Plixorafenib breakthrough status raises the stakes for FORE Biotherapeutics in BRAF-mutant high-grade glioma

FORE Biotherapeutics won FDA breakthrough status for plixorafenib in high-grade glioma. Read what this changes and what risks still remain.

FORE Biotherapeutics won FDA breakthrough status for plixorafenib in high-grade glioma. Read what this changes and what risks still remain.